<SEC-DOCUMENT>0000950170-24-117946.txt : 20241029
<SEC-HEADER>0000950170-24-117946.hdr.sgml : 20241029
<ACCEPTANCE-DATETIME>20241029080012
ACCESSION NUMBER:		0000950170-24-117946
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20241029
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241029
DATE AS OF CHANGE:		20241029

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Eledon Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001404281
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36620
		FILM NUMBER:		241402726

	BUSINESS ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612
		BUSINESS PHONE:		949-238-8090

	MAIL ADDRESS:	
		STREET 1:		19800 MACARTHUR BLVD.
		STREET 2:		SUITE 250
		CITY:			IRVINE
		STATE:			CA
		ZIP:			92612

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Novus Therapeutics, Inc.
		DATE OF NAME CHANGE:	20170511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tokai Pharmaceuticals Inc
		DATE OF NAME CHANGE:	20070622
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>eldn-20241029.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-10-29T07:43:28.4241+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:eldn="http://www.eledon.com/20241029" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_9ee0f249-e055-4b10-8942-7ba73a2bf812" name="dei:EntityCentralIndexKey" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b">0001404281</ix:nonNumeric><ix:nonNumeric id="F_15ce3dcb-65ab-4f63-8694-8eaaf6fbbb52" name="dei:AmendmentFlag" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="eldn-20241029.xsd"/></ix:references><ix:resources><xbrli:context id="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001404281</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-29</xbrli:startDate><xbrli:endDate>2024-10-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="border-top:2.25pt double #000000;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5.75pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES<br/>SECURITIES AND EXCHANGE COMMISSION<br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_065ad219-9671-47cb-aeb7-ebb8dd45ca0c" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:6pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span><ix:nonNumeric id="F_de778d89-b4ef-4fed-ae75-950a6a27d2c7" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">October 29, 2024</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40%;font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33cf3adf-9f3f-4c38-819a-9b830ba14455" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:3pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:20%;box-sizing:content-box;"/>
    <td style="width:18%;box-sizing:content-box;"/>
    <td style="width:41%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_17da0ac4-2eb2-465e-ab75-936b0a3f2614" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_67a3b36a-d5e7-415d-bd93-36935d4b972a" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-36620</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_3cbdf319-f5e7-4eb8-9823-d7b28edd10d7" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">20-1000967</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or Other Jurisdiction<br/>of Incorporation)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission File Number)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer<br/>Identification No.)</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_8974daeb-4e4c-476c-8850-23785ec6052a" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">19800 MacArthur Blvd.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_e13b270e-079a-4c9d-a8c5-a742bf4afc81" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 250</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_5169eb73-648c-41a0-b21c-3ffcf3e92df1" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Irvine</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_df8a70bf-b314-40a2-97f1-fb731f658ac6" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_ae6ad1ff-3b02-4cb5-8c7a-a569d07ebeb7" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92612</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td colspan="3" style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of Principal Executive Offices)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;margin-right:0.02986111111111111in;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Registrant&#8217;s Telephone Number, Including Area Code:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_bd09c5da-3303-440b-b6a2-d2192a1ef76e" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">949</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span><span><ix:nonNumeric id="F_2cf1d8ad-81e4-4e8a-b4a3-9bc256ad5742" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">238-8090</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100%;box-sizing:content-box;"/>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;text-align:left;">
    <td style="padding-top:0.125in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40%;font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;margin-right:40%;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:9.35pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_963237dc-486b-48aa-8575-a41c46533d34" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b5cec8f-6d87-4348-9b23-50e99a9b75f1" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a526e02b-2eb2-4fd4-81a5-0a4916b29c32" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6pt;margin-bottom:0;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f639f978-5376-4091-80e9-07b9906fc07f" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:9pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:15%;box-sizing:content-box;"/>
    <td style="width:1%;box-sizing:content-box;"/>
    <td style="width:45%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Title of each class</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading<br/>Symbol(s)</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"><br/>Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_b76174a3-c12d-4022-9e55-fa868a8183e6" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.001 par value</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9588d47c-951e-44b7-bc7c-2c74e3a39487" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ELDN</span></ix:nonNumeric></span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_9f76f8bb-bd38-4e44-86b2-37199ab04fc6" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8239;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8239;240.12b-2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:10pt;"><ix:nonNumeric id="F_5895cac8-102e-4f0c-9563-f993d577520a" contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On October 29, 2024, Eledon Pharmaceuticals Inc. (the &#8220;Company&#8221;) issued a press release announcing initial data from subjects with type 1 diabetes treated with tegoprubart, the Company&#8217;s investigational anti-CD40L antibody, as part of an immunosuppression regimen following islet transplantation in an investigator-initiated trial at the University of Chicago Medicine&#8217;s Transplantation Institute. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Also, on October 29, 2024, the Company updated its investor presentation, which is posted on the Company&#8217;s website at </span><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">https://ir.eledon.com/news-and-events/publications-and-presentations</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">  </span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be, or be deemed, incorporated by reference in any filings under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), unless the Company specifically states that the information is to be considered &#8220;filed&#8221; under the Exchange Act or incorporates it by reference into a filing under the Securities Act or the Exchange Act.</span></p>
  <p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.1%;box-sizing:content-box;"/>
    <td style="width:86.9%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="eldn-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release, dated October 29, 2024.</span></a></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;text-align:right;">
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-top:0.01in;padding-left:0.01in;vertical-align:top;padding-bottom:0.01in;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="z-index:-3;min-height:0.5in;position:relative;"></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6%;box-sizing:content-box;"/>
    <td style="width:44%;box-sizing:content-box;"/>
    <td style="width:4%;box-sizing:content-box;"/>
    <td style="width:46%;box-sizing:content-box;"/>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Eledon Pharmaceuticals, Inc.</span></p></td>
   </tr>
   <tr style="word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">October 29, 2024</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;"> </span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;border-bottom:0.25pt solid;"><p style="font-size:10pt;margin-top:4.3pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ David-Alexandre C. Gros, M.D.</span></p></td>
   </tr>
   <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-top:0.01in;vertical-align:top;"><p style="font-size:10pt;margin-top:0.7pt;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Name: David-Alexandre C. Gros, M.D.<br/>Title: Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:0.5in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>eldn-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><img src="img20068692_0.jpg" alt="img20068692_0.jpg" style="width:186px;height:47px;"></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">-</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">First two out of three subjects treated with tegoprubart as part of immunosuppression regimen to prevent transplant rejection achieved insulin independence and remain insulin free, with glucose control in the normal range; Third subject was recently transplanted and is on trajectory for insulin independence</font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">-</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">Islet engraftment in the first two subjects with tegoprubart estimated three to five times higher than engraftment in three comparable subjects receiving standard of care tacrolimus-based immunosuppression</font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">-</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">Treatment with tegoprubart was generally well tolerated </font></div></div>
  <p style="margin-left:10%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div class="item-list-element-wrapper" style="margin-left:6.667%;display:flex;margin-top:0;justify-content:center;align-items:baseline;margin-bottom:8pt;min-width:3.333%;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;font-style:italic;min-width:3.571084182443509%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">-</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">Study data to be presented by UChicago Medicine&#x2019;s team in oral presentation at the 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;font-style:italic;min-width:fit-content;"> IPITA/HSCI/Breakthrough T1D Stem Cells Summit</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">IRVINE, Calif., October 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (&#x201c;Eledon&#x201d;) (NASDAQ: ELDN) today announced positive data for the first three islet transplant recipients treated with an immunosuppression regimen that includes tegoprubart, the Company&#x2019;s investigational anti-CD40L antibody, for prevention of islet transplant rejection in subjects with type 1 diabetes (T1D). The investigator-initiated trial, conducted by the research team at the University of Chicago Medicine&#x2019;s Transplantation Institute, demonstrated potentially the first human cases of insulin independence achieved using an anti-CD40L monoclonal antibody therapy without the use of tacrolimus, the current standard of care for prevention of transplant rejection. The first two subjects achieved insulin independence and normal hemoglobin A1C (HbA1c) levels, a measure of average blood glucose, post-transplant. The third subject, who recently received an islet transplant, decreased insulin use by more than 60% three days following the procedure and continues on an insulin independence trajectory.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">  </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Subjects on study received islet transplants combined with induction therapy, mycophenolate mofetil (MMF), and tegoprubart, given every third week by intravenous (IV) infusion. The first two subjects achieved insulin independence and presented stable islet graft function at approximately three months and six months post-transplant, respectively. Islet engraftment, measured by graft</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">function standardized to the number of islets infused, was three to five times higher than three comparable subjects outside this study who received tacrolimus-based immunosuppression, suggesting treatment with tegoprubart is less toxic to transplanted islets resulting in improved graft survival and function. Treatment was generally well tolerated in all subjects with no unexpected adverse events or hypoglycemic episodes. After initial islet transplant, the first participant reduced insulin requirements by over 60% and normalized blood glucose control. The first patient then achieved insulin independence approximately two weeks after the second islet transplantation procedure.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">The data are being featured in an oral presentation at the International Pancreas and Islet Transplantation Association (IPITA), Harvard Stem Cell Institute (HSCI), and Breakthrough T1D (formerly JDRF) 5</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Aptos',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> Annual Summit on Stem Cell Derived Islets on Tuesday, October 29, 2024.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#x201c;We are very pleased that tegoprubart played a pivotal role in yet another landmark advance in transplantation research through the work of Dr. Witkowski, Dr. Fung and their team at UChicago Medicine,&#x201d; said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. &#x201c;Following promising results in kidney allotransplant procedures as well as heart and kidney xenograft procedures, these data from subjects following islet transplantation further demonstrate tegoprubart&#x2019;s potential to protect transplanted organs and cells. Dr. Witkowski&#x2019;s study also further reinforces prior study results showing that tegoprubart may offer a favorable safety and efficacy profile compared to tacrolimus-based immunosuppression regimens.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#x201c;These data are another step in our quest to achieve a path for functional cures in type 1 diabetes,&#x201d; said Piotr Witkowski, M.D., Ph.D., Director, Pancreas and Islet Transplant Program, UChicago Medicine and one of the study&#x2019;s lead investigators. &#x201c;For more than 30 years, we have been looking for options that can deliver target levels of immunosuppression without the side effects associated with standard of care, including toxicity to the kidneys, central nervous system and islet cells, and increased risk of diabetes and hypertension. These data further support tegoprubart as a novel immunosuppression option that can play a central role in advancing islets transplantation as a potentially transformational alternative for subjects with type 1 diabetes.&#x201d;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#x201c;Breakthrough T1D is proud to fund and support this research and is encouraged by the tegoprubart study showing that subjects who received islet transplants with a tacrolimus-free immunosuppressive regimen are making insulin again,&#34; said Breakthrough T1D Chief Scientific Officer Sanjoy Dutta, Ph.D. &#34;Islet replacement therapies are a key priority for Breakthrough T1D, and we&#x2019;re committed to driving research that moves us toward a world where these therapies are available to the broader T1D community. Achieving this goal requires novel approaches to keep transplanted cells functional with a tolerable immunosuppression regimen. These results are an important step toward that goal, and we look forward to seeing additional data.&#34;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Efficacy and Safety Results</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">The first participant was a 42-year-old female with a baseline weight of 88 kg/194 lbs (BMI of 30). At 90 days post-transplant, the participant&#x2019;s HbA1c level improved to 6.0% (from 8.4% at baseline)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">and daily insulin dose decreased to 16 units per day (from 80 units per day at baseline). After 16 weeks, the participant received a second islet transplant, and approximately two weeks later achieved insulin independence, maintaining improved HbA1c levels of 5.4% afterwards.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">The second participant was a 30-year-old female with a baseline weight of 50 kg/110 lbs (BMI of 21). This patient stopped insulin support (from 60 units per day at baseline) four weeks after the islet transplant. Her HbA1c levels improved to 5.8% and below (from 8.5% at baseline) starting at seven weeks after the transplant.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">The third participant was a 37-year-old male with a baseline weight of 92 kg/203 lbs (BMI of 30) with a baseline HbA1C of 9.3%. This patient was discharged home on day three post-transplant, requiring 29 units of insulin (from 90 units per day at baseline).</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">The treatment was generally well tolerated in all subjects with no unexpected adverse events, severe hypoglycemic episodes, or graft rejection.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">In January 2024, Eledon announced that it would be supplying tegoprubart for this investigator-led clinical trial with the UChicago Medicine Transplantation Institute for pancreatic islet transplantation in subjects with type 1 diabetes (NCT06305286). Tegoprubart is the cornerstone component of the chronic immunosuppressive regimen for trial participants and is being evaluated for the prevention of transplant rejection in the trial. Funding for the study includes grants from Breakthrough T1D (formerly known as JDRF) and The Cure Alliance.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">About Islet Transplantation for Type 1 Diabetes</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Pancreatic islet transplantation is a minimally invasive procedure developed to provide blood glucose control for subjects with type 1 diabetes and minimize or eliminate dependence on insulin. During the procedure, pancreatic islets containing insulin-producing beta cells are isolated from the pancreas of a deceased organ donor and infused through a small catheter into the patient&#x2019;s liver. The islet cells lodge in small blood vessels in the liver and release insulin. Post-procedure, subjects remain on immunosuppression therapy to prevent transplant rejection.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">About Eledon Pharmaceuticals and tegoprubart</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company&#x2019;s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company&#x2019;s website at www.eledon.com.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
  <div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Forward-Looking Statements</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company&#x2019;s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, expected or future results of tegoprubart trials and its ability to prevent rejection in connection with islet cell transplantation or kidney transplantation, as well as other statements containing the words &#x201c;believes,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;plans,&#x201d; &#x201c;expects,&#x201d; &#x201c;estimates,&#x201d; &#x201c;intends,&#x201d; &#x201c;predicts,&#x201d; &#x201c;projects,&#x201d; &#x201c;targets,&#x201d; &#x201c;looks forward,&#x201d; &#x201c;could,&#x201d; &#x201c;may,&#x201d; and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: risks relating to the safety and efficacy of our drug candidates; risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment; and risks relating to costs of clinical trials and the sufficiency of the company&#x2019;s capital resources to fund planned clinical trials. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company&#x2019;s actual results to differ significantly from the forward-looking statements contained herein, are discussed in our quarterly 10-Q, annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Investor Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Stephen Jasper<br>Gilmartin Group<br>(858) 525 2047<br>stephen@gilmartinir.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Jenna Urban<br>Berry &amp; Company Public Relations<br>(212) 253 8881<br>jurban@berrypr.com</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">Source: Eledon Pharmaceuticals</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Aptos',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:8pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div class="page-node-content"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img20068692_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img20068692_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !1 3X# 2(  A$! Q$!_\0
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M6_Y\-8_[\Q?_ !RO-_AW\-H?'-A>W,FIO9FVE6,*L(?=D9SU%=G_ ,,^VO\
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MI% 'R[>>/]>?PEJOA/Q"L\TKB,127 (FA99%8J^>2" >O.?;II? O_D?Y/\
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M>]U6/Q-?PE+*VS]E#C_6R=-P]E]?7'H:]/\ BG_R336_^N2?^C%H \8^"?\
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M\BWIW_7NG\JTZS/#G_(MZ=_U[I_*M.O&J_'+U9];AOX,/1?D%%%%9FX4444
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M14&G7YU"*:0V=U:^7,\06Y3:7"G&]1G[I['O0!:CCCAB6*)%2- %5%& H'0
M51US1[;Q!HEWI5YO%O<IL8H<,.X(]P0#6A10!P?@SX5Z7X-U=]3AO+FZN#&8
MT\T!0@.,G ZGC%=Y163KFN)HDFE*\#2C4+]+($-C865B&]_NXQ[T 7-2T^#5
M=,NM/NE+6]S$T4@!P=K#!P?6O-;#X$>'K:=WN[V]NXR,*A*IMYZY YKU2B@
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M'35**?9?D%%%%0;!1110 5Q_Q3_Y)IK?_7)/_1BUV%<?\4_^2::W_P!<D_\
M1BT ;UQXBT2UA::?5[".->K-<(!_.O*KX?:/AGXZU6WC:/3=0OO.LPRE=Z[D
M!D /9B/TKTZ/PAX9BD62/P[I".IR&6RC!'X[:Q_BF /AGK0 P!$G_HQ: $&F
M>.-0MC?'Q%!IEQ(-\>GI9)+%%Z([M\Q/0$C'? J?1_$FK:SX,FO;;3X6UV"1
M[66U+[8UG1]K<D_='WL9SCBNKKR8ZG?:3X,\5W-A,UNQ\2W$<MRJ;C!$TJAW
M ]@: .FGT?QO!9M=0^*XKB]0>8+1]/C6!SUV9'S@=LYS5?7/&EZOP_TGQ'I,
M \^[FM_]';!W;FPT>?<Y&?QJI?6/@:QTP7DEP=;O'4^0KW[W,UTY' 50W4\=
M  /:LQ?^2/\ A#_K^LO_ $;0!U:VWBC1]*U74M2\0Q7K+8R21VZ621K!*%+
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M0 4444 %%%% !1110 5C^*O^17U#_KE_4444 ;%97B/_ ) %S_P#_P!"%%%
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(W\S110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>eldn-20241029.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-10-29T07:43:28.8373+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.eledon.com/20241029" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:eldn="http://www.eledon.com/20241029" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="eldn-20241029.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="10091.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45620922052944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 29, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 29,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Eledon Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001404281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-1000967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">19800 MacArthur Blvd.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irvine<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">238-8090<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ELDN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MTG1X#SY['R73>RHY_U=3_ 102P,$%     @ !4!=69>*NQS     $P(   L
M  !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%
MG;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XU
MA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.
M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,B
MM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  %0%U9.JJBYT !
M   \ @  #P   'AL+W=O<FMB;V]K+GAM;(U176O#, S\*\8_8$G+5EAI!F/=
M1V%L91U]=V*E$;6M8*OMUE\_)2&LL)<]R3J)T]UY<:*X+XGVZLN[D K=,+?S
M+$M5 ]ZD*VHAR*2FZ U+&W=9:B,8FQH ]BZ;YODL\P:#OEN,7.N873;$4#%2
M$+ #M@BG]#OO6G7$A"4ZY.]"]V\'6GD,Z/$,MM"Y5JFATPM%/%-@XS95).<*
M/1D&6XB,U1]XTXG\-&7J$3;EAQ$AA9[E0EAC3-QO]/Q&-!Y!EH?NP/2$CB$N
M#<-SI$.+8=?1B(OLPD:?PUB'$.?Q/S%276,%2ZH.'@(/.49PG<"0&FR35L%X
M*/2XHNZ#58^!)22U"@.5['9.Y?3*#JY9Y%YD&.<H@[BR@_!1K84: ]@W.9 $
ME^2J=51=Z7FFUS>36TGHX-R#8._AE8P=S8\?=_<#4$L#!!0    (  5 75DD
M'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.UD3T.
M@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&RGBU_[\E.GV@4
M=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0DBBZ0=@S9)[N
MF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2XLM,EJ*H,AF*
M*I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+ P04    "  %
M0%U999!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX;6RMDTU.PS 0
MA:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-K'C>O,^>EZS>
MCQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+Y8-0P1-XJBA[
ME.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4ZD2HN7/08&<B
M+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#VQH%.JB]XY8:
M8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)W55D(TADIJ]X
M(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA
M/UY_ 5!+ 0(4 Q0    (  5 75D'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ !4!=658C[>3N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ !4!=69E<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  %0%U9"QLL7&H$   U$0  &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ !4!=69^@&_"Q @  X@P   T              ( !K0P  'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  %0%U9EXJ[',     3 @  "P
M    @ &)#P  7W)E;',O+G)E;'-02P$"% ,4    "  %0%U9.JJBYT !   \
M @  #P              @ %R$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ !4!=620>FZ*M    ^ $  !H              ( !WQ$  'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ !4!=6660>9(9 0  SP,
M !,              ( !Q!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/  D "0 ^ @  #A0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="eldn-20241029.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="eldn-20241029.htm">eldn-20241029.htm</File>
    <File>eldn-20241029.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "eldn-20241029.htm": {
   "nsprefix": "eldn",
   "nsuri": "http://www.eledon.com/20241029",
   "dts": {
    "inline": {
     "local": [
      "eldn-20241029.htm"
     ]
    },
    "schema": {
     "local": [
      "eldn-20241029.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_c0b30006-eb2b-49a3-9dcf-a0921772d02b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20241029.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c0b30006-eb2b-49a3-9dcf-a0921772d02b",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "eldn-20241029.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.eledon.com/20241029/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-117946-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-117946-xbrl.zip
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MWQ*L!7TGB8AC,2(?9,*24+*87-:]'L PPP8YCF-R@=5R<B%RD=T(WB@;[1:
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M'.3=GAP6+0YO: ]ZZ6(URMF(C@ L*I(-XO,\+-( O%##/U#AQ(?5(Q ^G^(
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M1I3,B<0F.)!9D9)<]@9QP1*1#O)X1')6R#P:J9I5A30 0,OLA6IS7':7,#Z
M=C+"DE']+0)1F]YB/8SW2<P4R5<UU]: )#)#$1.G-JA)Q(,;DJ)%#4NQ=2V#
M%3M5[V82V)=4K5/\H8O>X;T7"[>"/ CT@JT@OF,:ILM#:GD.V$<>8]2S79LR
M2P\MQS9-;CXYY?5?F2P Q9@.-$BJY);\?N W2-,X8$ 1!=#E4P#]^8WO6M;A
M0W;5<Y%9A0Y ZB0^2']BL^G% *P>R[ KEIG99(I[2_=UE[0_7!##U!I0\$[D
MSSER9 7B=5X$\5J!'8K0BZC#/9=:IN6!+V"8U-:$[S,_<.VGKQE=@@8+ >_)
M]6<0F2 WX]=+N7>X(+T*&??)5K<8U8T)RIW:$SVF6PO,5E7R=9(NLPU' *E5
M6PTB;H%7RVRJ,<O7G<#P0_/)ONR73*#,Q?.=U+$4J,>S\R@"K_;5DC#@A(83
M2'E0"NL6I\9^\/9Q!%V6?9TD'3FF'_FN1VW3=:BE^3KU0!!3S0U\7W.B4'.C
M-9-T)\\'(ML1]DJ$;0IJX:F:CR'LJNQ]PE[[>2#^=S@/9&7]=V>#E6Z-R, Q
MZL\[)42)C,K- 6RV7D!<RUQAU^$*&R)U^[MT8SW8S69RLI9:TYR-F1CCF,GS
MIE%L(MRM=CA<X=&FY?DE89>$,<OS]:P.+\8D>1.I/\U\-9DXKXVTKC*&&"G/
M21SUH.S^NG(L=G3UBNE*$=19=?*%DEBBMI! QT/;\.;.$/A^>;\O/=<W<!W=
MQ97;4#<X> J&07UAV]";YWC,TSU3/#GIM++51KH1**6S/)DLC*6#80W3?UFD
MX=<#\C^ >4TG8("1&Q8/7O3&^:T2-%M(M[[M>=QR0^K;.CA$5N#2((1'(W0M
M83+3M[PGYY%6NJQ48^LCVM-/)V<[TOR!23-RG<@+ AIPT\.]7Q;UG,"@IJO[
M/@LT*WIZ'G\M4NLP@3K2ZU[ !57DJJG[BR;OC.6<_44^QFG 8O*995]%L?FT
MF8?/#5V.7K]/(*B3< SZ"!*,2*B6?6&87\%:$>K\@IDU69D3&*  W%UC6/\Z
M2V^++L:.^KA.RW+"1223\H"O<E5*L^><>WIWW*E)]I'5W$/,TC/]0[5 5=>!
MWH!T^GA"&"8UE'$H#((_\BC5V;8Q-'57?:+UQO:L(F_VY.#GH[/3!33SP/G=
MV-V" ++M^7;(0H_JF@'J-=)0T3HFC7S?Y+;KVH:VIJVK]=@_JJ&WRY$_?^SX
MQR:83O0-47,  F:NW)+WTDBZ()5$+,("I%*2JK#K(!>J%(!9):O@I3OJ+@U2
MWMN!<ZOZBD?8^:V$KI%:$Q@V?,G$C<RA7C2^4HJ%(9[(A87Q0B+.,IZ7:2I\
M4<S7W&?CF.^D]&H\AB>6(Z -G1DX[=S/OUQDFW*V<%E-!1'1<KL6-$FYJ.O
MN.9?NQ+%8DBYS,IIP[CXH)<<UE<;X=?[-[/\9Y 7,AK5;:M2%$CM&U>VW*V1
M=,>N?X7O\G8HJBZC:>%]3(?3'Z#A\K4"J@P,L CT6HO%MVR45Q'L-5\K\PU#
MZ,'[!S:5];;F!9Q.(7K$!;L>SS$=Q&6BVH<3<G?776/3++85HO@\(;,'81^0
M^>?BEA?J[:-,0ZO+T XK=:F>],.W8$+F Q")#*0C;GT#(A,,Y#%+$A"@H4HC
M3(#^0*9R5C 296F/Y(/@/\!_>2F(\>8JHA,N62 * *# RP*AR?*CN$[[V2
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MGL^?GKRXNLR>^&L Y%^&%QX;=9N3=L$'\8B$;("I$BIP6-X[7(68<@"Z7"W
MM85 =%D<8;@(&U)60E4 EYX&&#A2S0'9=],,P.6SL8YM](Z=%7:B62O46:'*
M@T/;@LT(KRE+> ?K:X;5:BQW!7!9_NG:XTFW'J_ODJF=@-C!NH/UI<'Z8BR$
M9:7K.M:Y%L9[P:AL;;-JV23PLV&\UXJ'7T<;.V=Z8_NU7QZ6FWF3G+ ;R>EQ
M+(8LX9D@[0;YF*5@R7QNG#S:DME*H;:-&F$'ZP[6I6!MN,L=][2NJ-GBK:,]
MT7I :(Q/IFEAGK:([MW8DNUB[Z\]]G[4Q(T$[W\Z:G:+7OS^_P%02P,$%
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ML4NB3O 79A0=<@M'ME?6Y)<AQ),;G54A3*L=@WX=):?;<!- 4J"C55RI1L(
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M=T0^01=41L>,.U@7K(BG>;X4@-=D"@#BU%N8/:_P,H/M9[*2!J?#9#PF!^%
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M_[V@_P-02P$"% ,4    "  %0%U9<M$9EM03  !9H0  $0
M@ $     96QD;BTR,#(T,3 R.2YH=&U02P$"% ,4    "  %0%U9Z51Z[H (
M   380  $0              @ $#%   96QD;BTR,#(T,3 R.2YX<V102P$"
M% ,4    "  %0%U9/6LE-!(5   V:   #P              @ &R'   96QD
B;BUE>#DY7S$N:'1M4$L%!@     #  , NP   /$Q      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>eldn-20241029_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="eldn-20241029.xsd" xlink:type="simple"/>
    <context id="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001404281</identifier>
        </entity>
        <period>
            <startDate>2024-10-29</startDate>
            <endDate>2024-10-29</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_9ee0f249-e055-4b10-8942-7ba73a2bf812">0001404281</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_15ce3dcb-65ab-4f63-8694-8eaaf6fbbb52">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_065ad219-9671-47cb-aeb7-ebb8dd45ca0c">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_de778d89-b4ef-4fed-ae75-950a6a27d2c7">2024-10-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_33cf3adf-9f3f-4c38-819a-9b830ba14455">Eledon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_17da0ac4-2eb2-465e-ab75-936b0a3f2614">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_67a3b36a-d5e7-415d-bd93-36935d4b972a">001-36620</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_3cbdf319-f5e7-4eb8-9823-d7b28edd10d7">20-1000967</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_8974daeb-4e4c-476c-8850-23785ec6052a">19800 MacArthur Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_e13b270e-079a-4c9d-a8c5-a742bf4afc81">Suite 250</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_5169eb73-648c-41a0-b21c-3ffcf3e92df1">Irvine</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_df8a70bf-b314-40a2-97f1-fb731f658ac6">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_ae6ad1ff-3b02-4cb5-8c7a-a569d07ebeb7">92612</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_bd09c5da-3303-440b-b6a2-d2192a1ef76e">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_2cf1d8ad-81e4-4e8a-b4a3-9bc256ad5742">238-8090</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_963237dc-486b-48aa-8575-a41c46533d34">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_4b5cec8f-6d87-4348-9b23-50e99a9b75f1">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_a526e02b-2eb2-4fd4-81a5-0a4916b29c32">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_f639f978-5376-4091-80e9-07b9906fc07f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_b76174a3-c12d-4022-9e55-fa868a8183e6">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_9588d47c-951e-44b7-bc7c-2c74e3a39487">ELDN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_9f76f8bb-bd38-4e44-86b2-37199ab04fc6">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_c0b30006-eb2b-49a3-9dcf-a0921772d02b"
      id="F_5895cac8-102e-4f0c-9563-f993d577520a">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
